Alendronic acid topical- Tritech Biopharmaceuticals

Drug Profile

Alendronic acid topical- Tritech Biopharmaceuticals

Alternative Names: Topical alendronate - Tritech Biopharmaceuticals; TR-563

Latest Information Update: 20 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tritech Biopharmaceuticals
  • Class Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Osteoporosis

Most Recent Events

  • 19 Apr 2017 Early research in Osteoporosis in Taiwan (Topical) prior to April 2017 (Tritech Biopharmaceuticals pipeline, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top